Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Access--Gilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access to lenacapavir for communities most affected by HIV. “South Africa is at the heart of global efforts to end HIV. With the country's launch of lenacapavir, there is now an opportunity to rapidly accelerate progress,” said Daniel O'Day, Chairma.

Business Wire • 9 hours ago

GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE

Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases

GlobeNewsWire • 20 hours ago

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

Zacks Investment Research • a day ago

GILD Reports Positive Results From Late-Stage Liver Disease Study

Gilead reports positive phase III IDEAL results as Livdelzi boosts ALP normalization in PBC patients, supporting regulatory discussions.

Zacks Investment Research • Jun 3, 2026

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Jun 3, 2026

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Gilead Sciences, Inc. (NASDAQ) on Tuesday released results from the Phase 3 IDEAL study in people with primary biliary cholangitis (PBC).

Benzinga • Jun 2, 2026

Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 weeks. The primary endpoint was defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥.

Business Wire • Jun 2, 2026

Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Seeking Alpha • May 29, 2026

Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today shared new results from a post hoc analysis showing that Livdelzi® (seladelpar) was associated with high and sustained rates of normalization of a key liver marker (ALP) in people living with primary biliary cholangitis (PBC). In an ongoing Phase 3 study, participants with elevated ALP levels (between 1.0 and 1.67×ULN) experienced reductions in ALP after treatment. These data highlight the potential role of Livdelz.

Business Wire • May 27, 2026

GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy

Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.

Zacks Investment Research • May 25, 2026